Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
2/5 17:20
Key PointsIts stock is down more than 11% this year, but there's reason for optimism....
|
|
|
2/5 17:20
Key PointsIts stock is down more than 11% this year, but there's reason for optimism....